All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Lymphoma Hub spoke to Charalampia Kyriakou, University College London, London, UK. We asked her to speak about the role hematopoietic stem cell transplantation in Waldenström's macroglobulinemia (WM).
Hematopoietic stem cell transplantation in Waldenström's macroglobulinemia
WM is a rare indolent lymphoma and is considered an orphan disease. In this video, Charalampia Kyriakou talks about which patients are suitable for transplant, the impact of the timing of transplantation, along with the introduction of novel therapies in patients with WM.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox